The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data.
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; immunocore; Janssen Oncology; Merck Serono; MSD
Consulting or Advisory Role - immunocore; Janssen-Cilag; MSD; Pfizer
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Janssen Oncology; Merck Serono; Pfizer
 
Joelle Collignon
Consulting or Advisory Role - Bayer (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Gilead Sciences (Inst); Novartis/Ipsen (Inst)
 
Rikke Løvendahl Eefsen
Consulting or Advisory Role - Amgen
Research Funding - Bristol-Myers Squibb/Medarex (Inst)
 
Audrius Ivanauskas
No Relationships to Disclose
 
Svetlana Shatunova
Research Funding - Cantargia AB
 
Irina Vetter
Research Funding - Cantargia AB
Patents, Royalties, Other Intellectual Property - Spider venom peptides and method
 
Elin Jaensson Gyllenbäck
Employment - Cantargia AB
Stock and Other Ownership Interests - Cantargia AB
Patents, Royalties, Other Intellectual Property - IL1RAP antibody - Cantargia, patent pending
 
Petter Skoog
Employment - Cantargia AB
Stock and Other Ownership Interests - Cantargia AB
 
Nedjad Losic
Employment - Cantargia AB
Stock and Other Ownership Interests - Cantargia AB
 
Dominique Tersago
Leadership - Cantargia AB
Consulting or Advisory Role - Cantargia AB
 
Hana Starobova
Research Funding - Cantargia AB